On 29th, March, Hasten Biopharmaceutical Co., Ltd (hereinafter referred to as "Hasten") signed a strategic cooperation agreement with Naxions on the "Hasten&Naxions Innovation Project". According to the agreement, Naxions will assist in promoting the accessibility of Hasten's high-quality products in specific markets through its multi-dimensional digital model to benefit more patients and jointly create greater social health value.

Xia Shaofei, CEO of Hasten, said, "Innovation is one of our core values, and is also the key to meet the needs of doctors and patients, while Naxions is a leader in pharmaceutical digital marketing innovation. We both believe that we together will be able to make better use of the online and offline digital platform innovation model to empower the efficient landing of high-quality products and treatment solutions, so as to better meet the growing needs of doctors and patients, as well as contribute to the realization of the strategic goal of 'Healthy China 2030'."